nevirapine and HIV
nevirapine has been researched along with HIV in 140 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 9.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
| "In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm(3) were randomized 1 : 1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for 7 days post-delivery) group." | 9.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
| "Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 9.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
| "Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 9.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 9.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 9.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 9.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 9.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| "To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 9.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
| "Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 7.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
| "The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 7.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 7.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 7.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| " The interaction of the NNRTI nevirapine (NVP) with HIV-1 reverse transcriptase (RT) is characterized by a preference for the open conformation of the fingers/thumb subdomains, and a reported variation of three orders of magnitude between the binding affinity of NVP for RT in the presence or absence of primer/template DNA." | 7.79 | Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP. ( DeRose, EF; London, RE; Mueller, GA; Zheng, X, 2013) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 7.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "Seventy HIV-infected patients receiving rifampin for active TB (TB group) and 70 HIV-mono-infected patients (control group) were enrolled to receive nevirapine 400mg/day-based ART." | 7.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 7.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
| "Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 7.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
| "Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 7.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
| "Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 7.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 7.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| "Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 6.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
| "The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine." | 6.17 | Resistance, drug failure, and disease progression. ( Richman, DD, 1994) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 5.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| "HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 5.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
| "030 mg ethinyl estradiol with either nevirapine (NVP) or efavirenz (EFV) in 34 HIV-positive women." | 5.17 | Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. ( Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S, 2013) |
| "Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 5.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
| "In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm(3) were randomized 1 : 1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for 7 days post-delivery) group." | 5.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
| "Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 5.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
| "From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir." | 5.15 | Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. ( Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A, 2011) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 5.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV." | 5.14 | Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010) |
| "Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 5.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 5.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 5.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| "To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 5.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
| " In a prospective study of 31 HIV-infected patients included in a salvage regimen with stavudine, nevirapine, nelfinavir, and saquinavir, viral load decreased a median of 1." | 5.09 | Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. ( Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001) |
| "Treatment of human immunodeficiency virus (HIV) infection with nevirapine in patients with < 400 CD4 cells/mm3 rapidly selects for virus with reduced susceptibility to nevirapine." | 5.08 | A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. ( Havlir, D; McLaughlin, MM; Richman, DD, 1995) |
| "Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk." | 4.12 | Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022) |
| " Younger age, male sex, less education, suboptimal adherence, receiving nevirapine, HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of NVL." | 3.96 | Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. ( Ao, TT; Barradas, DT; Bello, G; Birhanu, S; Brown, K; Frederix, K; Haas, AD; Hakim, AJ; Jahn, A; Jonnalagadda, S; Justman, JE; Kalua, T; Kim, E; Low, A; Mugurungi, O; Mulenga, LB; Musuka, G; Parekh, B; Patel, H; Philip, NM; Radin, E; Rogers, JH; Sachathep, K; Saito, S; Schwitters, AM; Sleeman, K; Thin, K; Tippett Barr, BA; Voetsch, AC; Williams, DB, 2020) |
| "Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 3.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
| "Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa." | 3.91 | Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 3.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
| " The present work envisages the development of a stealth anti-CD4 conjugated immunoliposomes containing two anti-retroviral drugs (nevirapine and saquinavir) that can selectively home into HIV infected cells through the CD4 receptor." | 3.81 | Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S; Sharma, S, 2015) |
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 3.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 3.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| "Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)." | 3.77 | Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011) |
| "To evaluate the effect of a previous single dose of nevirapine given to prevent mother-to-child transmission of human immunodeficiency virus (HIV) on virologic and immunologic measures after months of an antiretroviral regimen containing either efavirenz or lopinavir-ritonavir." | 3.77 | Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. ( Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H, 2011) |
| "Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy." | 3.77 | Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011) |
| "Seventy HIV-infected patients receiving rifampin for active TB (TB group) and 70 HIV-mono-infected patients (control group) were enrolled to receive nevirapine 400mg/day-based ART." | 3.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 3.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 3.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
| "Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 3.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
| "Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 3.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
| "Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 3.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
| " 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine (4'-Ed4T), a novel thymidine analog, has potent anti-human immunodeficiency virus (HIV) activity, maintains considerable activity against multidrug-resistant HIV strains, and is less inhibitory to mitochondrial DNA synthesis in cell culture than its progenitor stavudine (D4T)." | 3.74 | Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. ( Baba, M; Cheng, YC; Dutschman, GE; Grill, SP; Hu, R; Lam, W; Paintsil, E; Tanaka, H, 2007) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 3.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| "Combinations of the human immunodeficiency virus (HIV) Tat protein antagonist Ro 24-7429 with either the HIV protease inhibitor Ro 31-8959 or the HIV reverse transcriptase inhibitors AZT (3'-azido-3'-deoxythymidine), ddC (2',3'-dideoxycytidine), ddI (2',3'-dideoxyinosine), and nevirapine were synergistic or additive in reducing HIV type 1 p24 antigen production in CEM cells or inhibiting HIV type 1-induced syncytium formation in HT4-6C cells." | 3.69 | Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. ( Connell, EV; Hsu, MC; Richman, DD, 1994) |
| "We have investigated viral breakthrough during a long-term culture of HIV-1-infected cells with the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 6-benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442), nevirapine and loviride (alpha-APA)." | 3.69 | Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. ( Baba, M; Makino, M; Nakade, K; Okamoto, M; Yamada, K; Yuasa, S, 1996) |
| "The nonnucleoside reverse transcriptase inhibitor nevirapine rapidly selects for mutant human immunodeficiency virus (HIV) in vivo." | 3.69 | Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. ( Eastman, S; Gamst, A; Havlir, DV; Richman, DD, 1996) |
| " As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
| "This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care." | 2.74 | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. ( Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW, 2009) |
| " Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment." | 2.71 | Follow-up measurements of Nevirapine plasma levels over a prolonged period. ( Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004) |
| "The study was conducted among 42 adult AIDS Clinical Trials Group sites and 7 National Hemophilia Foundation centers." | 2.69 | A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T ( Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C, 1998) |
| "Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 2.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 1.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| "Patients in the TREAT Asia HIV Observational Database receiving first-line ART for ≥ 6 months were included." | 1.40 | Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. ( Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F, 2014) |
| "The surrogate markers of HIV/AIDS progression include CD4 T cell count and plasma viral load." | 1.40 | MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. ( Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB, 2014) |
| "Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz." | 1.31 | The tolerability of efavirenz after nevirapine-related adverse events. ( Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000) |
| " Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel." | 1.29 | 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. ( Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993) |
| "When nevirapine was combined with zidovudine (AZT) and didanosine (ddI), patients' CD4 counts rose significantly and viral load was reduced to below detectable levels." | 1.29 | FDA approves first new class of HIV drugs. Food and Drug Administration. ( , 1996) |
Research
Studies (140)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (19.29) | 18.2507 |
| 2000's | 41 (29.29) | 29.6817 |
| 2010's | 63 (45.00) | 24.3611 |
| 2020's | 9 (6.43) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Williams, TM | 1 |
| Ciccarone, TM | 1 |
| MacTough, SC | 1 |
| Rooney, CS | 1 |
| Balani, SK | 1 |
| Condra, JH | 1 |
| Emini, EA | 1 |
| Goldman, ME | 1 |
| Greenlee, WJ | 1 |
| Kauffman, LR | 1 |
| Janssen, PA | 1 |
| Lewi, PJ | 1 |
| Arnold, E | 1 |
| Daeyaert, F | 1 |
| de Jonge, M | 1 |
| Heeres, J | 1 |
| Koymans, L | 1 |
| Vinkers, M | 1 |
| Guillemont, J | 2 |
| Pasquier, E | 1 |
| Kukla, M | 1 |
| Ludovici, D | 1 |
| Andries, K | 2 |
| de Béthune, MP | 2 |
| Pauwels, R | 1 |
| Das, K | 1 |
| Clark, AD | 1 |
| Frenkel, YV | 1 |
| Hughes, SH | 1 |
| Medaer, B | 1 |
| De Knaep, F | 1 |
| Bohets, H | 1 |
| De Clerck, F | 1 |
| Lampo, A | 1 |
| Williams, P | 1 |
| Stoffels, P | 1 |
| Paintsil, E | 1 |
| Dutschman, GE | 1 |
| Hu, R | 1 |
| Grill, SP | 1 |
| Lam, W | 1 |
| Baba, M | 2 |
| Tanaka, H | 1 |
| Cheng, YC | 1 |
| Massari, S | 2 |
| Daelemans, D | 2 |
| Manfroni, G | 2 |
| Sabatini, S | 1 |
| Tabarrini, O | 2 |
| Pannecouque, C | 6 |
| Cecchetti, V | 2 |
| Le Van, K | 1 |
| Cauvin, C | 1 |
| de Walque, S | 1 |
| Georges, B | 1 |
| Boland, S | 1 |
| Martinelli, V | 1 |
| Demonté, D | 1 |
| Durant, F | 1 |
| Hevesi, L | 1 |
| Van Lint, C | 1 |
| Benjahad, A | 1 |
| Oumouch, S | 1 |
| Decrane, L | 1 |
| Palandjian, P | 1 |
| Vernier, D | 1 |
| Queguiner, L | 1 |
| Hertogs, K | 2 |
| Grierson, DS | 1 |
| Nguyen, CH | 1 |
| Asaftei, S | 1 |
| De Clercq, E | 3 |
| Casano, G | 1 |
| Dumètre, A | 1 |
| Hutter, S | 1 |
| Azas, N | 1 |
| Robin, M | 1 |
| Banerjee, D | 1 |
| Yogeeswari, P | 1 |
| Bhat, P | 1 |
| Thomas, A | 1 |
| Srividya, M | 1 |
| Sriram, D | 1 |
| Garnsey, MR | 1 |
| Matous, JA | 1 |
| Kwiek, JJ | 1 |
| Coltart, DM | 1 |
| Tian, Y | 1 |
| Du, D | 1 |
| Rai, D | 1 |
| Wang, L | 1 |
| Liu, H | 1 |
| Zhan, P | 2 |
| Liu, X | 2 |
| Sancineto, L | 1 |
| Iraci, N | 1 |
| Barreca, ML | 1 |
| Corazza, G | 1 |
| Marcello, A | 1 |
| Müller, R | 1 |
| Mulani, I | 1 |
| Basson, AE | 2 |
| Pribut, N | 2 |
| Hassam, M | 1 |
| Morris, L | 2 |
| van Otterlo, WAL | 1 |
| Pelly, SC | 2 |
| Pardo-Vargas, A | 1 |
| Ramos, FA | 1 |
| Cirne-Santos, CC | 1 |
| Stephens, PR | 1 |
| Paixão, ICP | 1 |
| Teixeira, VL | 1 |
| Castellanos, L | 1 |
| Bala, V | 1 |
| Jangir, S | 1 |
| Mandalapu, D | 1 |
| Gupta, S | 1 |
| Chhonker, YS | 1 |
| Lal, N | 1 |
| Kushwaha, B | 1 |
| Chandasana, H | 1 |
| Krishna, S | 1 |
| Rawat, K | 1 |
| Maikhuri, JP | 1 |
| Bhatta, RS | 1 |
| Siddiqi, MI | 1 |
| Tripathi, R | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Patel, RV | 1 |
| Park, SW | 1 |
| Peet, J | 1 |
| Selyutina, A | 1 |
| Bredihhin, A | 1 |
| Veale, CG | 1 |
| van Otterlo, WA | 1 |
| Elgaher, WA | 1 |
| Sharma, KK | 1 |
| Haupenthal, J | 1 |
| Saladini, F | 1 |
| Pires, M | 1 |
| Real, E | 1 |
| Mély, Y | 1 |
| Hartmann, RW | 1 |
| Xiao, T | 1 |
| Tang, JF | 1 |
| Meng, G | 1 |
| Zhu, YY | 1 |
| Liu, GY | 1 |
| Xu, ZQ | 1 |
| Wu, FS | 1 |
| Gu, SX | 1 |
| Chen, FE | 1 |
| Gao, P | 1 |
| Song, S | 1 |
| Wang, Z | 2 |
| Sun, L | 1 |
| Zhang, J | 1 |
| Boyce, CL | 1 |
| Sils, T | 1 |
| Ko, D | 1 |
| Wong-On-Wing, A | 1 |
| Beck, IA | 2 |
| Styrchak, SM | 1 |
| DeMarrais, P | 1 |
| Tierney, C | 2 |
| Stranix-Chibanda, L | 1 |
| Flynn, PM | 1 |
| Taha, TE | 1 |
| Owor, M | 1 |
| Fowler, MG | 3 |
| Frenkel, LM | 2 |
| Chua, KY | 1 |
| Tey, KE | 1 |
| Larsen, A | 1 |
| Magasana, V | 1 |
| Dinh, TH | 1 |
| Ngandu, N | 1 |
| Lombard, C | 2 |
| Cheyip, M | 1 |
| Ayalew, K | 1 |
| Chirinda, W | 1 |
| Kindra, G | 1 |
| Jackson, D | 1 |
| Goga, A | 1 |
| Abdullahi, ST | 1 |
| Soyinka, JO | 1 |
| Olagunju, A | 1 |
| Bolarinwa, RA | 1 |
| Olarewaju, OJ | 1 |
| Bakare-Odunola, MT | 1 |
| Winterberg, M | 1 |
| Tarning, J | 1 |
| Owen, A | 1 |
| Khoo, S | 1 |
| Haas, AD | 1 |
| Radin, E | 1 |
| Hakim, AJ | 1 |
| Jahn, A | 1 |
| Philip, NM | 1 |
| Jonnalagadda, S | 1 |
| Saito, S | 1 |
| Low, A | 1 |
| Patel, H | 1 |
| Schwitters, AM | 1 |
| Rogers, JH | 1 |
| Frederix, K | 1 |
| Kim, E | 1 |
| Bello, G | 1 |
| Williams, DB | 1 |
| Parekh, B | 1 |
| Sachathep, K | 1 |
| Barradas, DT | 1 |
| Kalua, T | 1 |
| Birhanu, S | 1 |
| Musuka, G | 1 |
| Mugurungi, O | 1 |
| Tippett Barr, BA | 1 |
| Sleeman, K | 1 |
| Mulenga, LB | 1 |
| Thin, K | 1 |
| Ao, TT | 1 |
| Brown, K | 1 |
| Voetsch, AC | 1 |
| Justman, JE | 1 |
| Yang, H | 1 |
| Chu, L | 1 |
| Wu, Y | 2 |
| Wang, W | 1 |
| Yang, J | 1 |
| Zhang, Q | 1 |
| Qiao, S | 1 |
| Li, X | 1 |
| Shen, Z | 1 |
| Zhou, Y | 1 |
| Liu, S | 1 |
| Deng, H | 1 |
| Afrane, AKA | 1 |
| Goka, BQ | 1 |
| Renner, L | 1 |
| Yawson, AE | 1 |
| Alhassan, Y | 1 |
| Owiafe, SN | 1 |
| Agyeman, S | 1 |
| Sagoe, KWC | 1 |
| Kwara, A | 1 |
| Prasertvit, P | 1 |
| Chareonyingwattana, A | 1 |
| Wattanakrai, P | 1 |
| Van de Wijer, L | 1 |
| Kinabo, GD | 1 |
| Mchaile, DN | 1 |
| de Mast, Q | 1 |
| Schellekens, AFA | 1 |
| van der Ven, AJAM | 1 |
| Murnane, PM | 1 |
| Strehlau, R | 2 |
| Shiau, S | 1 |
| Patel, F | 1 |
| Mbete, N | 1 |
| Hunt, G | 1 |
| Abrams, EJ | 2 |
| Coovadia, A | 2 |
| Kuhn, L | 3 |
| Su, S | 1 |
| Fairley, CK | 1 |
| Sasadeusz, J | 1 |
| He, J | 1 |
| Wei, X | 1 |
| Zeng, H | 1 |
| Jing, J | 1 |
| Mao, L | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Vaz, P | 1 |
| Buck, WC | 1 |
| Bhatt, N | 1 |
| Bila, D | 1 |
| Auld, A | 1 |
| Houston, J | 1 |
| Cossa, L | 1 |
| Alfredo, C | 1 |
| Jobarteh, K | 1 |
| Sabatier, J | 1 |
| Macassa, E | 1 |
| Sousa, A | 1 |
| DeVos, J | 1 |
| Jani, I | 1 |
| Yang, C | 1 |
| Giacomelli, A | 1 |
| Riva, A | 1 |
| Falvella, FS | 1 |
| Oreni, ML | 1 |
| Cattaneo, D | 1 |
| Cheli, S | 1 |
| Renisi, G | 1 |
| Di Cristo, V | 1 |
| Lupo, A | 1 |
| Clementi, E | 1 |
| Rusconi, S | 1 |
| Galli, M | 1 |
| Ridolfo, AL | 1 |
| Wang, X | 1 |
| Guo, G | 1 |
| Zheng, J | 1 |
| Lu, L | 1 |
| Ji, S | 1 |
| Xu, Y | 1 |
| Han, D | 1 |
| Peng, X | 1 |
| Lu, X | 1 |
| Brockmeyer, NH | 1 |
| Wu, N | 1 |
| Potty, RS | 1 |
| Sinha, A | 1 |
| Sethumadhavan, R | 1 |
| Isac, S | 1 |
| Washington, R | 1 |
| Notter, J | 1 |
| Bregenzer, A | 1 |
| Vernazza, P | 1 |
| Kahlert, CR | 1 |
| Apangu, P | 1 |
| Izudi, J | 1 |
| Bajunirwe, F | 1 |
| Mulogo, E | 1 |
| Batwala, V | 1 |
| Mazanderani, AH | 1 |
| Murray, TY | 1 |
| Sherman, GG | 1 |
| Snyman, T | 1 |
| George, J | 1 |
| Avenant, T | 1 |
| Goga, AE | 2 |
| Pepper, MS | 1 |
| du Plessis, N | 1 |
| Kiage, JN | 1 |
| Heimburger, DC | 1 |
| Nyirenda, CK | 1 |
| Wellons, MF | 1 |
| Bagchi, S | 1 |
| Chi, BH | 1 |
| Koethe, JR | 1 |
| Arnett, DK | 1 |
| Kabagambe, EK | 1 |
| Fillekes, Q | 2 |
| Mulenga, V | 1 |
| Kabamba, D | 1 |
| Kankasa, C | 3 |
| Thomason, MJ | 2 |
| Cook, A | 1 |
| Chintu, C | 1 |
| Gibb, DM | 2 |
| Walker, AS | 2 |
| Burger, DM | 2 |
| Zheng, X | 1 |
| Mueller, GA | 1 |
| DeRose, EF | 1 |
| London, RE | 1 |
| Muro, EP | 1 |
| Chunda, C | 1 |
| Aitken, S | 1 |
| Kisanga, ER | 1 |
| Ramokolo, V | 1 |
| Fadnes, LT | 1 |
| Doherty, T | 1 |
| Jackson, DJ | 1 |
| Chhagan, M | 1 |
| Van den Broeck, J | 1 |
| Dickinson, L | 1 |
| Chaponda, M | 1 |
| Carr, DF | 1 |
| van Oosterhout, JJ | 1 |
| Kumwenda, J | 1 |
| Lalloo, DG | 1 |
| Pirmohamed, M | 1 |
| Heyderman, RS | 1 |
| Khoo, SH | 1 |
| Mir, F | 1 |
| Qamar, FN | 1 |
| Baig-Ansari, N | 1 |
| Abro, AG | 1 |
| Abbas, SQ | 1 |
| Kazi, MA | 1 |
| Rizvi, A | 1 |
| Zaidi, AK | 1 |
| Munshi, SU | 1 |
| Panda, H | 1 |
| Holla, P | 1 |
| Rewari, BB | 2 |
| Jameel, S | 1 |
| Boettiger, DC | 1 |
| Kerr, S | 1 |
| Ditangco, R | 1 |
| Merati, TP | 1 |
| Pham, TT | 1 |
| Chaiwarith, R | 1 |
| Kiertiburanakul, S | 1 |
| Li, CK | 1 |
| Kumarasamy, N | 3 |
| Vonthanak, S | 1 |
| Lee, C | 1 |
| Van Kinh, N | 1 |
| Pujari, S | 1 |
| Wong, WW | 1 |
| Kamarulzaman, A | 1 |
| Zhang, F | 1 |
| Yunihastuti, E | 1 |
| Choi, JY | 1 |
| Oka, S | 1 |
| Ng, OT | 1 |
| Kantipong, P | 1 |
| Mustafa, M | 1 |
| Ratanasuwan, W | 1 |
| Sohn, A | 1 |
| Law, M | 1 |
| Mavura, DR | 1 |
| Masenga, EJ | 1 |
| Minja, E | 1 |
| Grossmann, H | 1 |
| Crump, JA | 1 |
| Bartlett, JA | 1 |
| Shearer, K | 1 |
| Brennan, AT | 1 |
| Maskew, M | 1 |
| Long, L | 1 |
| Berhanu, R | 1 |
| Sanne, I | 1 |
| Fox, MP | 1 |
| Ramana, LN | 1 |
| Sharma, S | 1 |
| Sethuraman, S | 1 |
| Ranga, U | 1 |
| Krishnan, UM | 1 |
| Palombi, L | 3 |
| Galluzzo, CM | 1 |
| Andreotti, M | 2 |
| Liotta, G | 2 |
| Jere, H | 1 |
| Sagno, JB | 1 |
| Luhanga, R | 1 |
| Mancinelli, S | 1 |
| Amici, R | 1 |
| Marazzi, MC | 3 |
| Vella, S | 2 |
| Giuliano, M | 3 |
| Lanzafame, M | 2 |
| Lattuada, E | 2 |
| Rigo, F | 1 |
| Nicole, S | 1 |
| Cucchetto, G | 1 |
| Vento, S | 2 |
| van Griensven, J | 1 |
| Choun, K | 1 |
| Chim, B | 1 |
| Thai, S | 1 |
| Lorent, N | 1 |
| Lynen, L | 1 |
| Dalvi, BR | 1 |
| Siddiqui, EA | 1 |
| Syed, AS | 1 |
| Velhal, SM | 1 |
| Ahmad, A | 1 |
| Bandivdekar, AB | 1 |
| Devarajan, PV | 1 |
| Bolaris, MA | 1 |
| Keller, MA | 1 |
| Robbins, BL | 1 |
| Podany, AT | 1 |
| Fletcher, CV | 1 |
| Olana, T | 1 |
| Bacha, T | 1 |
| Worku, W | 1 |
| Tadesse, BT | 1 |
| Gray, GE | 1 |
| Saloojee, H | 1 |
| Church, JD | 3 |
| Omer, SB | 3 |
| Guay, LA | 3 |
| Huang, W | 2 |
| Lidstrom, J | 1 |
| Musoke, P | 3 |
| Mmiro, F | 1 |
| Jackson, JB | 3 |
| Eshleman, SH | 3 |
| Li, T | 1 |
| Dai, Y | 1 |
| Kuang, J | 1 |
| Jiang, J | 1 |
| Han, Y | 1 |
| Qiu, Z | 1 |
| Xie, J | 1 |
| Zuo, L | 1 |
| Li, Y | 1 |
| Walter, J | 1 |
| Semrau, K | 1 |
| Sinkala, M | 1 |
| Thea, DM | 1 |
| Aldrovandi, GM | 1 |
| Moorthy, A | 2 |
| Gupta, A | 1 |
| Bhosale, R | 1 |
| Tripathy, S | 1 |
| Sastry, J | 1 |
| Kulkarni, S | 1 |
| Thakar, M | 1 |
| Bharadwaj, R | 1 |
| Kagal, A | 1 |
| Bhore, AV | 1 |
| Patil, S | 1 |
| Kulkarni, V | 1 |
| Venkataramani, V | 1 |
| Balasubramaniam, U | 1 |
| Suryavanshi, N | 1 |
| Ziemniak, C | 1 |
| Gupte, N | 1 |
| Bollinger, R | 1 |
| Persaud, D | 2 |
| Shipton, LK | 1 |
| Wester, CW | 1 |
| Stock, S | 1 |
| Ndwapi, N | 1 |
| Gaolathe, T | 1 |
| Thior, I | 1 |
| Avalos, A | 1 |
| Moffat, HJ | 1 |
| Mboya, JJ | 1 |
| Widenfelt, E | 1 |
| Essex, M | 1 |
| Hughes, MD | 2 |
| Shapiro, RL | 1 |
| Ammann, AJ | 1 |
| Mwatha, A | 2 |
| Bagenda, D | 2 |
| Donnell, D | 1 |
| Nakabiito, C | 1 |
| Eure, C | 2 |
| Bakaki, P | 2 |
| Matovu, F | 2 |
| Thigpen, MC | 2 |
| McConnell, M | 2 |
| Zoppini, G | 1 |
| Concia, E | 1 |
| Parkin, N | 1 |
| Marlowe, N | 1 |
| Mwinga, K | 1 |
| Vermund, SH | 1 |
| Chen, YQ | 1 |
| Read, JS | 1 |
| Urassa, W | 1 |
| Carpenetti, N | 1 |
| Valentine, M | 1 |
| Goldenberg, RL | 1 |
| Jaffar, S | 1 |
| Amuron, B | 1 |
| Foster, S | 1 |
| Birungi, J | 1 |
| Levin, J | 1 |
| Namara, G | 1 |
| Nabiryo, C | 1 |
| Ndembi, N | 1 |
| Kyomuhangi, R | 1 |
| Opio, A | 1 |
| Bunnell, R | 1 |
| Tappero, JW | 1 |
| Mermin, J | 1 |
| Coutinho, A | 1 |
| Grosskurth, H | 1 |
| Corbett, AH | 1 |
| Hosseinipour, MC | 1 |
| Nyirenda, J | 1 |
| Kanyama, C | 1 |
| Rezk, NL | 1 |
| Mkupani, P | 1 |
| Sichali, D | 1 |
| Tien, H | 1 |
| Kashuba, AD | 1 |
| Mwansambo, C | 1 |
| Weigel, R | 1 |
| Kazembe, P | 1 |
| Torpey, K | 1 |
| Kasonde, P | 1 |
| Dirks, R | 1 |
| Bweupe, M | 1 |
| Kabaso, M | 1 |
| Mandala, J | 1 |
| Sangiwa, G | 1 |
| Beldjebel, I | 1 |
| Vujcikova, J | 1 |
| Sokolova, J | 1 |
| Krcmery, V | 1 |
| Manosuthi, W | 1 |
| Tantanathip, P | 1 |
| Chimsuntorn, S | 1 |
| Eampokarap, B | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Sungkanuparph, S | 1 |
| Bachani, D | 1 |
| Rajasekaran, S | 1 |
| Deshpande, A | 1 |
| Chan, PL | 1 |
| Srikantiah, P | 1 |
| Cournil, A | 1 |
| Coudray, M | 1 |
| Kouanfack, C | 1 |
| Essomba, CN | 1 |
| Tonfack, CA | 1 |
| Biwolé-Sida, M | 1 |
| Delaporte, E | 1 |
| Bork, K | 1 |
| Laurent, C | 1 |
| Nielsen-Saines, K | 1 |
| Zhang, C | 1 |
| Sun, Y | 1 |
| Hong, C | 1 |
| Xiang, K | 1 |
| Guo, Y | 1 |
| Bartlam, M | 1 |
| Lou, Z | 1 |
| Meyers, T | 1 |
| Sherman, G | 1 |
| Tsai, WY | 1 |
| Chen, YH | 1 |
| Dlamini, JN | 1 |
| Hu, Z | 1 |
| Somaroo, H | 1 |
| Highbarger, HC | 1 |
| Follmann, DA | 1 |
| Dewar, RL | 1 |
| Pau, AK | 1 |
| Ukwe, CV | 1 |
| Ekwunife, OI | 1 |
| Udeogaranya, OP | 1 |
| Iwuamadi, UI | 1 |
| Pérez Pedrero, D | 1 |
| Górgolas, M | 1 |
| Fernández Guerrero, ML | 1 |
| Bommenel, T | 1 |
| Launay, O | 1 |
| Meynard, JL | 1 |
| Gilquin, J | 1 |
| Katlama, C | 1 |
| Lascaux, AS | 1 |
| Mahamat, A | 1 |
| Martinez, V | 1 |
| Pradier, C | 1 |
| Rouveix, E | 1 |
| Simon, A | 1 |
| Costagliola, D | 1 |
| Abgrall, S | 1 |
| Ellis, GM | 1 |
| Huang, S | 1 |
| Hitti, J | 2 |
| Martins, AN | 1 |
| Arruda, MB | 1 |
| Aleixo, AW | 1 |
| Pires, AF | 1 |
| Greco, DB | 1 |
| de M Brindeiro, R | 1 |
| Tanuri, A | 1 |
| Van Dyke, RB | 1 |
| Ngo-Giang-Huong, N | 1 |
| Shapiro, DE | 1 |
| Frenkel, L | 1 |
| Britto, P | 1 |
| Roongpisuthipong, A | 1 |
| Yuthavisuthi, P | 1 |
| Prommas, S | 1 |
| Puthanakit, T | 1 |
| Achalapong, J | 1 |
| Chotivanich, N | 1 |
| Rasri, W | 1 |
| Cressey, TR | 2 |
| Maupin, R | 1 |
| Mirochnick, M | 1 |
| Jourdain, G | 1 |
| Chokephaibulkit, K | 1 |
| Capparelli, E | 1 |
| Sirisanthana, V | 1 |
| Muresan, P | 1 |
| Hongsiriwon, S | 1 |
| Ngampiyaskul, C | 1 |
| Limwongse, C | 1 |
| Wittawatmongkol, O | 1 |
| Aurpibul, L | 1 |
| Kabat, B | 1 |
| Toye, M | 1 |
| Smith, ME | 1 |
| Eksaengsri, A | 1 |
| McIntosh, K | 1 |
| Yogev, R | 1 |
| Pennings, PS | 1 |
| Landolt, NK | 1 |
| Phanuphak, N | 1 |
| Ubolyam, S | 1 |
| Pinyakorn, S | 1 |
| Kriengsinyot, R | 1 |
| Ahluwalia, J | 1 |
| Thongpaeng, P | 1 |
| Gorowara, M | 1 |
| Thammajaruk, N | 1 |
| Chaithongwongwatthana, S | 1 |
| Lange, JM | 1 |
| Ananworanich, J | 1 |
| McMahon, DK | 1 |
| Zheng, L | 1 |
| Chan, ES | 1 |
| Halvas, EK | 1 |
| Hong, F | 1 |
| Kabanda, J | 1 |
| Taulo, F | 1 |
| Bonhomme, J | 1 |
| Wallis, CL | 1 |
| Klingman, KL | 1 |
| Mellors, JW | 1 |
| Montaner, JS | 1 |
| Cahn, P | 1 |
| Zala, C | 1 |
| Casssetti, LI | 1 |
| Losso, M | 1 |
| Hall, DB | 1 |
| Wruck, J | 1 |
| McDonough, M | 1 |
| Gigliotti, M | 1 |
| Robinson, PA | 1 |
| Parienti, JJ | 1 |
| Massari, V | 1 |
| Descamps, D | 1 |
| Vabret, A | 1 |
| Bouvet, E | 1 |
| Larouzé, B | 1 |
| Verdon, R | 1 |
| Tebas, P | 1 |
| Yarasheski, K | 1 |
| Henry, K | 2 |
| Claxton, S | 1 |
| Kane, E | 1 |
| Bordenave, B | 1 |
| Klebert, M | 1 |
| Powderly, WG | 1 |
| Check, E | 1 |
| Sienz, M | 1 |
| Zilly, M | 1 |
| Ebigbo, A | 1 |
| Knipper, A | 1 |
| Winzer, R | 1 |
| Klinker, H | 1 |
| Langmann, P | 1 |
| Goulder, PJ | 1 |
| Blanckenberg, N | 1 |
| Dong, K | 1 |
| Gianotti, N | 1 |
| Boeri, E | 1 |
| Maillard, M | 1 |
| Serra, G | 1 |
| Ratti, D | 1 |
| Gallotta, G | 1 |
| Vacchini, D | 1 |
| Tremolada, Y | 1 |
| Castagna, A | 1 |
| Dailly, E | 1 |
| Tribut, O | 1 |
| Tattevin, P | 1 |
| Arvieux, C | 1 |
| Perré, P | 1 |
| Raffi, F | 1 |
| Jolliet, P | 1 |
| DeJesus, E | 1 |
| Piliero, PJ | 1 |
| Summers, K | 1 |
| Wire, MB | 1 |
| Stein, DS | 1 |
| Masterman, A | 1 |
| Lou, Y | 1 |
| Min, SS | 1 |
| Shelton, MJ | 1 |
| Martinson, NA | 1 |
| Gray, G | 1 |
| Moodley, D | 1 |
| Pillay, V | 1 |
| Cohen, S | 1 |
| Dhlamini, P | 1 |
| Puren, A | 1 |
| Bhayroo, S | 1 |
| Steyn, J | 1 |
| McIntyre, JA | 1 |
| Guidotti, G | 1 |
| Pirillo, MF | 1 |
| Villani, P | 1 |
| Mancini, MG | 1 |
| Cusato, M | 1 |
| Germano, P | 1 |
| Loureiro, S | 1 |
| Ceffa, S | 1 |
| Regazzi, M | 1 |
| Venkatesh, KK | 1 |
| Devaleenal, B | 1 |
| Palanivel, V | 1 |
| Cecelia, AJ | 1 |
| Muthu, S | 1 |
| Yepthomi, T | 1 |
| Mayer, KH | 1 |
| Flanigan, T | 1 |
| Shekelle, P | 1 |
| Maglione, M | 1 |
| Geotz, MB | 1 |
| Wagner, G | 1 |
| Hilton, L | 1 |
| Carter, J | 1 |
| Chen, S | 1 |
| Tringle, C | 1 |
| Mojica, W | 1 |
| Newberry, S | 1 |
| Mubiru, M | 1 |
| Downing, R | 1 |
| Greenberg, AE | 1 |
| Toure, S | 1 |
| Kouadio, B | 1 |
| Seyler, C | 1 |
| Traore, M | 1 |
| Dakoury-Dogbo, N | 1 |
| Duvignac, J | 1 |
| Diakite, N | 1 |
| Karcher, S | 1 |
| Grundmann, C | 1 |
| Marlink, R | 1 |
| Dabis, F | 1 |
| Anglaret, X | 1 |
| Gozlan, M | 1 |
| Connell, EV | 1 |
| Hsu, MC | 1 |
| Richman, DD | 4 |
| Havlir, D | 1 |
| McLaughlin, MM | 1 |
| Rennie, J | 1 |
| Cohen, J | 2 |
| Nowak, MA | 1 |
| Voelker, R | 1 |
| Okamoto, M | 1 |
| Makino, M | 1 |
| Yamada, K | 1 |
| Nakade, K | 1 |
| Yuasa, S | 1 |
| Erlander, SR | 1 |
| Havlir, DV | 1 |
| Eastman, S | 1 |
| Gamst, A | 1 |
| Collins, DO | 1 |
| Sakamoto, A | 1 |
| Miller, V | 1 |
| Staszewski, S | 1 |
| Boucher, CA | 1 |
| Phair, JP | 1 |
| Erice, A | 1 |
| Balfour, HH | 1 |
| Fischl, MA | 1 |
| Kmack, A | 1 |
| Liou, SH | 1 |
| Kenton, A | 1 |
| Hirsch, MS | 1 |
| Phair, J | 1 |
| Martinez, A | 1 |
| Kahn, JO | 1 |
| Titmuss, SJ | 1 |
| Keller, PA | 1 |
| Griffith, R | 1 |
| Cherry, M | 2 |
| Clarke, S | 1 |
| Harrington, P | 1 |
| Barry, M | 1 |
| Mulcahy, F | 1 |
| Gutiérrez, F | 1 |
| Moltó, J | 1 |
| Escolano, C | 1 |
| Mora, A | 1 |
| Pasquau, F | 1 |
| Gregori, J | 1 |
| Nogueira, E | 1 |
| Casado, JL | 1 |
| Dronda, F | 1 |
| Sabido, R | 1 |
| Antela, A | 1 |
| Martí-Belda, P | 1 |
| Dehertogh, P | 1 |
| Moreno, S | 1 |
| James, JS | 1 |
| Bowers, M | 1 |
| Mascolini, M | 1 |
| Link, D | 1 |
| Doepel, L | 1 |
| Folkers, G | 1 |
| Howorka, S | 1 |
| Cheley, S | 1 |
| Bayley, H | 1 |
Clinical Trials (17)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania[NCT03227653] | 144 participants (Actual) | Observational | 2017-06-19 | Completed | |||
| The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719] | Phase 2 | 66 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150] | 2,579 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| [NCT00618176] | Phase 4 | 198 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726] | 1,435 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| Prevention of Maternal to Infant HIV Transmission in India[NCT00061321] | Phase 3 | 770 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671] | Phase 3 | 3,720 participants | Interventional | Completed | |||
| Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial[NCT03058484] | 1,830 participants (Actual) | Interventional | 2015-05-01 | Completed | |||
| Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models[NCT02776254] | 3,100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [NCT00398684] | Phase 3 | 1,792 participants | Interventional | 2001-01-31 | Completed | ||
| Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3[NCT00000747] | Phase 2 | 10 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy[NCT00001029] | Phase 2 | 654 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)[NCT00000781] | Phase 2 | 1,292 participants | Interventional | Completed | |||
| A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease[NCT00001075] | 55 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Exclusive Breastfeeding Rates in Burkina Faso
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 310 |
| No Intervention | 161 |
Exclusive Breastfeeding Rates in South Africa
The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 56 |
| No Intervention | 30 |
Exclusive Breastfeeding Rates in Uganda
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 323 |
| No Intervention | 161 |
Infant Morbidity, 2 Week Diarrhoea Prevalence
(NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 104 |
| No Intervention | 101 |
Area Under the Curve Pharmacokinetic Outcome for LPV/r. (AUC ug*hr/mL)
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug*hr/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 99.7 |
| At Day 30 Ppm | NA |
Four (4) Hour Concentration Pharmacokinetic Outcome for LPV/r (C4hour ug/mL).
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 10.78 |
| At Day 30 Ppm | 12.96 |
Maximum Concentration Pharmacokinetic Outcome for LPV/r (Cmax ug/mL) .
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 11.2 |
| At Day 30 Ppm | NA |
Median HIV-1 Viral Load at 24 Weeks Postpartum in Women
(NCT00109590)
Timeframe: at 24 weeks postpartum
| Intervention | log10 copies/mL (Median) |
|---|---|
| Arm A : LPV/r x 7d | 4.3 |
| Arm B : no LPV/r | 3.9 |
| Arm C: LPV/r x 30d | 4.0 |
Number of Women With Grade >=3 Events After Start of Study Treatment
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
| Intervention | participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 2 |
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 2 |
Pre-dose Concentration Pharmacokinetic Outcome for LPV/r (Cpredose ug/mL).
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 6.08 |
| At Day 30 Ppm | 9.17 |
Resistance Mutations in HIV Infected Infants
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
| Intervention | participants (Number) |
|---|---|
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 0 |
The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay (OLA) in Plasma
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 3.6 |
| Arm B : no LPV/r | 7.1 |
| Arm C : LPV/r x 30d | 5.3 |
The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations for the Subgroup of Women With Plasma HIV RNA >= 500 Copies/ml At Entry
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A: LPV/r x 7d | 4.9 |
| Arm B: no LPV/r | 9.5 |
| Arm C : LPV/r x 30d | 7.0 |
The Proportion of Women Who Develop One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay in Plasma (Sampling Was Done at Days 10,21,30, and Weeks 5,6, and 8 Postpartum).
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 7.1 |
| Arm B : no LPV/r | 12.5 |
| Arm C: LPV/r x 30d | 5.3 |
Proportion of Women With New NVP Resistance Mutation Within 8 Weeks Postpartum Who Had a NVP Resistance Mutation Detected at 72 Weeks Postpartum.
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
| Intervention | participants (Number) | |
|---|---|---|
| OLA in plasma samples | OLA in PBMC | |
| Arm A : LPV/r x 7d | 0 | 0 |
| Arm B : no LPV/r | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 1 |
The Proportion of Women With Any New ZDV, ddI, or LPV/r Resistance Mutations.
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
| Arm A : LPV/r x 7d | 0 | 0 | 0 |
| Arm B : no LPV/r | 1.78 | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 0 | 0 |
Number of Participants Who Discontinued Study Treatment Prematurely
participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 2 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 5 |
Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping
"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 3 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 1 |
Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 1 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12
"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 5 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 2 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 2 |
Reviews
7 reviews available for nevirapine and HIV
| Article | Year |
|---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; | 2005 |
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Inte | 2015 |
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV | 2009 |
Antiretroviral (ARV) drug resistance in the developing world.
Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV | 2007 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
AIDS pathogenesis: from models to viral dynamics in patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection | 1995 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
Trials
23 trials available for nevirapine and HIV
| Article | Year |
|---|---|
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans | 2013 |
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif | 2013 |
Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Asian People; CD4 Lymphocyte | 2008 |
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma | 2009 |
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; | 2010 |
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re | 2010 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies | 2011 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig | 2011 |
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopro | 2013 |
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; | 2013 |
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans; | 2003 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy | 2004 |
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human | 2004 |
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot | 2006 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio | 2007 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical | 2007 |
A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Female | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combinati | 2001 |
Other Studies
111 other studies available for nevirapine and HIV
| Article | Year |
|---|---|
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Topics: Animals; Antiviral Agents; Base Sequence; Biological Availability; HIV; HIV Reverse Transcriptase; H | 1993 |
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
Topics: Anti-HIV Agents; Cell Line; Dideoxynucleotides; Dose-Response Relationship, Drug; HeLa Cells; HIV; H | 2007 |
Studies on anti-HIV quinolones: new insights on the C-6 position.
Topics: Anti-HIV Agents; HIV; Humans; Quinolones; Structure-Activity Relationship; Transcription, Genetic; V | 2009 |
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Cell Survival; Cell Transformation, Viral; Computer Simul | 2009 |
Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
Topics: Anti-HIV Agents; Cell Line; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Iod | 2009 |
"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line; Dendrimers; HIV; Humans; Static Electricity; Structure | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; M | 2010 |
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Asymmetric total synthesis of (+)- and (-)-clusianone and (+)- and (-)-clusianone methyl enol ether via ACC alkylation and evaluation of their anti-HIV activity.
Topics: Alkylation; Anti-HIV Agents; Benzophenones; Benzoquinones; Bridged Bicyclo Compounds; Cell Line; Eth | 2011 |
Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; HIV; HIV Rev | 2014 |
Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
Topics: Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; HIV; Humans; Ligands; Microbial Sensit | 2014 |
Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; HIV; HIV Reverse Transcriptase; Indoles; Microbia | 2014 |
Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.
Topics: Anti-HIV Agents; Cell Line, Transformed; Diterpenes; Dose-Response Relationship, Drug; HIV; Humans; | 2014 |
Dithiocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies.
Topics: Anti-Infective Agents; Female; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Docki | 2015 |
Antiretroviral (HIV-1) activity of azulene derivatives.
Topics: Anti-HIV Agents; Azulenes; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV; Humans; | 2016 |
Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Click Chemistry; Cyclization; Dose-Response Relationship, Drug; HIV; HIV Reverse Tr | 2016 |
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Respons | 2016 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Huma | 2020 |
Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse T | 2021 |
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections; | 2022 |
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection | 2022 |
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi | 2019 |
Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
Topics: Artemether; Artemether, Lumefantrine Drug Combination; Cytochrome P-450 CYP2B6; Genotype; HIV; Nevir | 2020 |
Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Eswatini; Female; | 2020 |
LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Female; Hair; HIV; HIV Infections; Humans; Mal | 2020 |
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; | 2021 |
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV; Humans; Nevirapine; Patch Tests; Pr | 2017 |
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Rit | 2018 |
Reply to Van de Wijer et al.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir | 2018 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistanc | 2020 |
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2018 |
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV | 2019 |
Changes in Lipid Indices in HIV+ Cases on HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia | 2019 |
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV | 2019 |
Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV; HIV Infecti | 2019 |
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor | 2019 |
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female | 2019 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Anti-HIV Agents; HIV; HIV Reverse Transcriptase; Kineti | 2013 |
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV | 2014 |
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P | 2014 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazi | 2014 |
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate | 2014 |
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; | 2015 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; | 2014 |
Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Carriers; HEK293 Cells; H | 2015 |
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; | 2015 |
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV; HI | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion Solvent Evaporation: In vitro and In vivo Evaluation.
Topics: Animals; Anti-HIV Agents; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Emulsions | 2016 |
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV | 2017 |
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant; | 2016 |
Breast-feeding, antiretroviral prophylaxis, and HIV.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Tra | 2008 |
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infec | 2008 |
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I | 2008 |
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopro | 2009 |
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug | 2009 |
No influence of nevirapine on vitamin D deficiency in HIV-infected patients.
Topics: Anti-HIV Agents; HIV; HIV Infections; Humans; Longitudinal Studies; Nevirapine; Vitamin D Deficiency | 2009 |
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
Topics: Age Factors; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Mutation; Nevirapine; Reag | 2009 |
Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Child; Child, Preschoo | 2010 |
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide | 2010 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV | 2010 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In | 2010 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C | 2011 |
A novel non-radioactive assay for HIV-RT (RdDp) based on pyrosequencing for high-throughput drug screening.
Topics: Anti-HIV Agents; Colorimetry; Diphosphates; Drug Evaluation, Preclinical; HIV; HIV Reverse Transcrip | 2010 |
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cli | 2011 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov | 2010 |
Nevirapine-induced agranulocytosis.
Topics: Agranulocytosis; Anti-HIV Agents; HIV; HIV Seropositivity; Humans; Male; Middle Aged; Nevirapine | 2011 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf | 2011 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes | 2011 |
Standing genetic variation and the evolution of drug resistance in HIV.
Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole | 2012 |
Resistant HIV in breast milk.
Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy | 2003 |
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro | 2004 |
Health minister ignites row over drugs for HIV mothers.
Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I | 2004 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious | 2004 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2006 |
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections | 2007 |
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans; | 2007 |
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'I | 2008 |
Update on HIV transmission and pathogenesis.
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV | 1995 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; | 1994 |
Triple whammy. Will an AIDS therapy live up to its advance billing?
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Drug Therapy, Combination; HIV; Hum | 1993 |
AIDS drugs. Harvard group makes a splash--twice.
Topics: Antiviral Agents; Didanosine; HIV; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors | 1993 |
Resisting the temptation.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Com | 1993 |
High turnover of HIV in blood revealed by new studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas | 1995 |
New HIV drugs cast in supporting roles.
Topics: Antiviral Agents; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibito | 1996 |
Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
Topics: Acetamides; Acetophenones; Cell Line, Transformed; HIV; HIV Core Protein p24; HIV-1; Humans; Nevirap | 1996 |
The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism.
Topics: Acquired Immunodeficiency Syndrome; Apoptosis; CD4-Positive T-Lymphocytes; Endopeptidases; Eosinophi | 1996 |
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HeLa Cells; HIV; HIV Infe | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do | 1996 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th | 1997 |
Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Topics: Binding Sites; Databases, Factual; HIV; HIV Reverse Transcriptase; Ligands; Molecular Structure; Nev | 1999 |
Mbeki gives AIDS scientists the cold shoulder.
Topics: Acquired Immunodeficiency Syndrome; Adult; Breast Feeding; Enzyme-Linked Immunosorbent Assay; Female | 2000 |
Diplomatic Mandela calls for action on HIV...as South Africa considers its options after free drugs offer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Drug Costs; Drug Industry; Female | 2000 |
The tolerability of efavirenz after nevirapine-related adverse events.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; | 2000 |
[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; End | 2000 |
New information on HIV rapid turnover--what does it mean?
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina | 1995 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
FDA approves first new class of HIV drugs. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibi | 1996 |
Nevirapine: new drug, new class, new questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combi | 1996 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
Nevirapine--first of a new class of drugs.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne | 1997 |
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections | 2001 |
Sequence-specific detection of individual DNA strands using engineered nanopores.
Topics: Base Pair Mismatch; Biosensing Techniques; Biotechnology; Cell Membrane; DNA; HIV; Lipid Bilayers; M | 2001 |
Nevirapine (Viramune).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; R | 2000 |